Skin Cancer

Recent FDA approvals have added to the growing number of treatment options for patients with advanced melanoma.

After a cancer diagnosis, patients and their caregivers must decide how much information to share with loved ones, and who should manage the communication plan.

Using sunscreen and protective clothing are good preventive measures.

By learning how to identify melanoma, patients can seek early diagnoses, potentially minimizing their treatment needs.

The FDA has expanded the approval for single-agent Keytruda to include the frontline treatment of patients with advanced melanoma regardless of BRAF status and to include the treatment of patients with Yervoy-refractory melanoma.

My letter to Ty, a young man taken before his time.

Former U.S. president Jimmy Carter once again provided an update on his health today.

I feel terror and beauty all around me, but it's OK to feel them both — they've gotten me this far.

Many patients who have had melanoma do not conduct regular skin self-examinations, and those who do check themselves do not use sufficient tools or techniques.

The approval was based on a substantial improvement in overall survival (OS) in a phase 3 study.

The approval was based on an extension in overall survival from two phase 3 studies.

Adding the MEK inhibitor Mekinist to the BRAF inhibitor Tafinlar significantly improves long-term outcomes while lowering certain adverse events associated with either agent alone.

Two-time cancer survivor discusses her fatigue and possible answers for it.

To gain insight into the recent flurry of FDA approvals in melanoma, CURE spoke with Tim Turnham, the executive director of the Melanoma Research Foundation.

It's exhausting trying to keep everybody positive about my progress.

The approval was based on an extension in progression-free survival in the phase 3 coBRIM study.

The approval is based on results from the phase 3 EORTC 18071 trial, in which adjuvant Yervoy reduced the risk of recurrence by 25 percent versus placebo.

The approval was based on results from the phase 3 OPTiM study in which Imlygic significantly extended durable response rates compared with GM-CSF.

"I think I can, I think I can," says a two-time cancer survivor.

Before I was diagnosed with metastatic melanoma, I lived in the sweet spot — both in life and in running.

Breast cancer and melanoma survivor ponders the impact of cancer on her capacity to cope with life changes.

Each phone call started the same way and ended with more bad news.

The combination was approved for patients with BRAF V600 wild-type unresectable or metastatic melanoma, based on results from a phase 2 study.

I wish my doctors knew more about the emotional aspects of cancer and were given more time with me.

Melanoma survivor vents about her "procedures" and discusses digital mole mapping.